In our previous in-silico study of cell-line panel data retrieved from the National Cancer Institute 60 (NCI60), oxaliplatin and 5-FU sensitivities were significantly correlated, and cells resistant to oxaliplatin showed significantly higher ERCC1 and DPD expression than sensitive cells.[11] Clinical samples also confirmed that the cancer cells of FOLFOX-treated patients expressed significantly more ERCC1 and DPD than cells of non-treated patients. The gene discussed is ERCC1; the disease is cancer.